In The News

Dapagliflozin Lowers Plasma Glucose Concentration and Improves Beta Cell Function

March 2015. This study was designed to examine the effects of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on beta cell function in patients with type 2 diabetes mellitus (T2DM). Twenty-four individuals with T2DM received dapagliflozin or placebo for 2 weeks, with a 75-gram oral glucose tolerance test (OGTT) and insulin clamp performed before and after treatment. During the OGTT, plasma glucose, insulin, and C-peptide concentrations were also measured.

Surge in Newly Identified Diabetes Among Medicaid Patients in 2014 Within Medicaid Expansion States Under the Affordable Care Act

March 22, 2015. Pursuant to the Affordable Care Act (ACA), 26 states and the District of Columbia expanded Medicaid in January 2014, while 24 states did not. Investigators identified the number of patients with newly identified diabetes among enrollees aged 19 to 64 years in states that expanded Medicaid vs those that did not. In the states that expanded Medicaid, the number of Medicaid-enrolled patients with newly identified diabetes increased by 23% (14,625 vs 18,020), compared with an increase of 0.4% (11,612 vs 11,653 patients) in the states that did not expand Medicaid.

Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial

March 10, 2015. This retrospective analysis was conducted to examine the safety and cardiovascular (CV) effects of saxagliptin in elderly (≥65 years, n=8561) and very elderly (≥75 years, n=2330) patients who participated in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial. The primary endpoint was a composite of CV mortality, myocardial infarction, or ischemic stroke; patients were followed for a median of 2.1 years.

Heart Failure and Mortality Outcomes in Patients With Type 2 Diabetes Taking Alogliptin Versus Placebo in EXAMINE

Concerns have been reported regarding excessive rates of in-hospital heart failure (HF) with DPP-4 inhibitors. This evaluation of data from EXAMINE, a multicenter, randomized, double-blind trial, assessed HF-related hospital admission rates in patients assigned to treatment with alogliptin (n=2701) or placebo (n=2679) and followed for a median of 533 days.

AACE Responds to “Unmanageable” Situation, Pushes Congress to Pass Improved Diabetes Care Legislation

The American Association of Clinical Endocrinologists (AACE) is leading more than 40 national organizations representing physicians, allied health professionals, patients, communities, and the medical industry in support of legislation that will improve care for individuals with diabetes, prediabetes, and associated illnesses.

Initial Combination of Empagliflozin and Linagliptin in Patients With Type 2 Diabetes

This 52-week randomized study was conducted to evaluate the efficacy and safety of combined therapy with empagliflozin and linagliptin in patients with type 2 diabetes (T2D). Mean baseline patient A1C was approximately 8%. Following a washout period, patients (N=677) were proportionally assigned to 1 of 5 study groups (listed with A1C reductions achieved at 24 weeks): empagliflozin 25 mg/linagliptin 5 mg (-1.08%); empagliflozin 10 mg/linagliptin 5 mg (-1.24%); empagliflozin 25 mg (-0.95%); empagliflozin 10 mg (-0.83%); or linagliptin 5 mg (-0.67%).

Preventable Major Cardiovascular Events Associated With Uncontrolled Glucose, Blood Pressure, and Lipids, and Active Smoking in Adults With Diabetes With and Without Cardiovascular Disease: A Contemporary Analysis

This study assessed the incidence of major cardiovascular (CV) hospitalization events and all-cause deaths among adults with diabetes with or without cardiovascular disease (CVD), inadequately controlled A1C, elevated LDL cholesterol (LDL-C) and blood pressure (BP), and current smoking. Participants were 859,617 adults with diabetes enrolled in U.S. integrated health care organizations between 2005 and 2011 (31% with existing CVD).

FDA Approves New Insulin Product, Toujeo

The U.S. Food and Drug Administration (FDA) has approved insulin Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL). Expected to be available in the United States by mid-2015, this once-daily, long-acting basal insulin has been approved to improve glycemic control in adults with type 1 and type 2 diabetes. This approval was based on FDA review of results from the EDITION clinical trial program, a series of international phase III studies evaluating the efficacy and safety of Toujeo in more than 3,500 adults with diabetes.

A Randomized Controlled Trial to Provide Adherence Information and Motivational Interviewing to Improve Diabetes and Lipid Control

This study assessed whether patients with medication adherence information (AI) provided to their physicians, with or without motivational interviewing (MI), was associated with improved diabetes and lipid control. Participants (N=1692) were members of a single large Michigan health system; they had A1C levels above target and were receiving oral antidiabetic and lipid-lowering medications. Patients were assigned to usual care (UC) or UC with AI or with AI + MI. The primary outcomes were A1C and LDL cholesterol levels at 18 months.

Gender-Based Differences in Glycemic Control and Hypoglycemia Prevalence in Patients With Type 2 Diabetes

This study was designed to evaluate the impact of patient gender on glucose control and hypoglycemia incidence in insulin-naïve patients with inadequately controlled type 2 diabetes (T2D). Investigators evaluated patient-level pooled data from 6 randomized controlled trials of insulin glargine or NPH insulin (N=2600; trials were 24-36 weeks duration). Mean baseline patient A1C was ~8.9%-9.0% and mean patient age was 57 years.

Pages